Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Precigen, Inc. (PGEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.3800+0.0500 (+3.76%)
At close: 04:00PM EDT
1.4300 +0.05 (+3.62%)
After hours: 06:54PM EDT
Advertisement
Sign in to post a message.
  • J
    James
    Jacob Plieth, ''Meanwhile, Precigen faces a different type of problem: a $201m convertible debt comes due for repayment in July 2023, but the group has just $142m in cash, and its market cap has fallen to $260m.

    With little chance of an equity raise at the current valuation and in the current market Precigen has mooted selling off non-core assets to raise the necessary cash. Wells Fargo analysts suggest that Precigen’s lead Actobiotics asset, AG019 for type 1 diabetes, could be the first to go.

    The company could also try to renegotiate the debt, but equity investors seldom come out well from such moves.''
  • M
    Mike
    Did PRGN-2009 just go to stage two or did that happen a while ago? it's updated on the study details this just happened Friday?
  • J
    Jas
    Daily volume appears to go lower and lower. Judie?
  • D
    Denmy
    Wells Fargo has are research report on PGEN. Interesting! Why they still have a price target of 17 is hard for me to grasp!
  • N
    Natural
    BioNTech CEO spoke about CAR-T's promise on May 9th, 2022 on the quarterly call and spoke about how CAR-T shows promise and will facilitate significant long-term growth. PGEN is ahead of BioNTech as PGEN is ONLY focused on Ultra CAR-T... multiple Phase IIs and a fast track approval. PGEN could be a $20+ stock by year-end.
    Bullish
  • J
    Jas
    10X from here would be great in next 1 to 2 years. $13.50, not greedy.
  • N
    Natural
    JMP Securities reiterated a buy after Q1 Earnings at $13 ... something will happen soon enough for PGEN and an FDA approval
  • N
    Natural
    BioNtech is showing the strong potential of CAR-T and PGEN is focused on Ultra CAR-T , an improved form of chimeric antigen receptors. It's clear that the future of eliminating cancer resides with this technology.... PGEN is beaten up but the tech is extremely promising and they only need to have 1 of their pipeline products succeed to show that the rest of their pipeline has the same potential.... could easily be a $10-20 billion company
    Bullish
  • E
    ExperiencedBioPharmGuy
    PGEN is crushing it. Rob Cos is a genius.
  • M
    Mike
    it was a good report today and sounds like prgn-2012 will make money in about a year and it's doesn't need to raise money. it is sad too and it sounds like it's not moving forward much with phase 2b-3 studies without partners.
  • J
    Joe Coolaid
    I added today at ,1.27 gift..💪
  • M
    Macrocosmonaut
    PGEN - OUTPERFORM - PT 22 USD

    This company has an excellent product portfolio and a great science.

    CAR-T Cell Therapy is a game changer in the field of cancer therapeutics.

    At present stock price levels the marcet cap is reflecting a extreme undervaluation.

    The MIDTERM PT is at 22 USD.

    Do your own due dilligence.

    M.
    Bullish
  • Y
    Yahoo Finance Insights
    Precigen reached a 52 Week low at 1.28
  • D
    Denmy
    At a 1.25, pgen in basketball terms needs a lot of three pointers to be a winner. Can they pull it off. Not Sure
  • M
    Macrocosmonaut
    PGEN - now this stock is able to be a 20-bagger...

    Realy nice to see undervalued stock at such low PPS.

    Do your own due dilligence.

    M.
    Bullish
  • Y
    Yahoo Finance Insights
    Precigen reached a 52 Week low at 1.18
  • N
    Natural
    May 9, 2022: Sahin, M.D., CEO and Co-Founder of BioNTech

    “We have enhanced our COVID-19 vaccine leadership and reported encouraging data for our first in-human CAR-T therapy in solid tumors. Driven by our execution in innovation, we believe we are well positioned to achieve multiple product launches in the coming years, which would facilitate significant long-term growth.”
    Bullish
  • M
    Macrocosmonaut
    PGEN - OUTPERFORM - 12 months PT 27 USD

    This stock is extremly undervalued. The proof of principle of the CART T Cell Therapy has been succesful validated.

    The CART - T Cell therapy reflects a paradigma change in the whole field of oncology, including malignant hematology.

    IMO.

    Do your own due dilligence.
    Bullish
  • C
    Caroline
    ⭐ Top Bullish Charts | April 2022 💰💵📈

    https://stockreport.tips/Bullish-Charts
  • m
    m
    Just got proxy to vote. Never remembered ever buying this. So many directors to vote for. What a quandary what to do? Thumbs please!
Advertisement
Advertisement